KRYS - CONSENSUS CO - Krystal Biotech, Inc.

Krystal Biotech, Inc. (KRYS) is a leading developer in the gene therapy niche for skin pathologies, investing colossal sums into creating innovative delivery methods for therapeutic genes. This price chart confirms market expectations, where the indicator stands at 393.77. The company's revenues are based on settlements with insurance companies for unique care provided to individuals with severe genetic epidermal defects. Effective partnerships with external manufacturers guarantee the stable, uninterrupted production of drugs.

The cost of Krystal Biotech, Inc. (KRYS) gene therapy for treating rare dermatological pathologies is factored into future cash flows via DCF calculations. The average investment bank price target aggregates these models, determining the gap between the current share price and the fundamental value. This indicator measures the market consensus regarding capitalization potential. The trend in the average investment bank price target allows for an assessment of the asset's valuation inertia. A high upside here signals volatility risk during the implementation of insurance reimbursement strategies.